The epidermal growth factor receptor (EGFR) has shown to be upregulated in 90% to 100% of the head and neck cancers.12 Cetuximab is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically to EGFR and inhibits receptor activation by competing with epidermal growth factor. Here, EGFR is linked to head and neck cancer.